Detection of High- and Low-Risk HPV DNA in Archived Breast Carcinoma Tissues from Ethiopian Women.
Journal
International journal of breast cancer
ISSN: 2090-3170
Titre abrégé: Int J Breast Cancer
Pays: Egypt
ID NLM: 101568103
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
06
2021
accepted:
29
09
2021
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
22
10
2021
Statut:
epublish
Résumé
Human papilloma virus (HPV) is involved in the development of cancer of the cervix, mouth and throat, anus, penis, vulva, or vagina, but it has not been much considered as a cause of breast cancer. Recently, a number of investigations have linked breast cancer to viral infections. High-risk HPV types, predominantly HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, are established as carcinogens in humans. In this study we aimed to detect 19 high-risk and 9 low-risk HPVs from archived breast tumor tissue among Ethiopian women. In this study, 75 breast cancer patients from Tikur Anbassa Specialized Hospital in Addis Ababa (Ethiopia) were included. HPV detection and genotyping were done using the novel Anyplex™ II HPV28 Detection Assay at the Orebro University Hospital, Sweden. The Anyplex™ II PCR System detects 19 high-risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 low-risk HPV types (6, 11, 40, 42, 43, 44, 54, 61, and 70). IHC for p16 was done using an automated system, the Dako Autostainer Link. Out of the 75 valid tests, two were found to be positive (2.7%) for HPV. One of the cases was positive for the high-risk HPV16 genotype while the other was positive both for the high-risk HPV39 and the low-risk HPV6. The cell cycle protein p16 was highly expressed in the case positive for the high-risk HPV16, but it was not expressed in the case positive for HPV39. The prevalence of HPV is low in Ethiopian breast cancer patients, but the role played by HPV in breast carcinogenesis among Ethiopian breast cancer patients cannot be commented based on these observations.
Sections du résumé
BACKGROUND
BACKGROUND
Human papilloma virus (HPV) is involved in the development of cancer of the cervix, mouth and throat, anus, penis, vulva, or vagina, but it has not been much considered as a cause of breast cancer. Recently, a number of investigations have linked breast cancer to viral infections. High-risk HPV types, predominantly HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, are established as carcinogens in humans. In this study we aimed to detect 19 high-risk and 9 low-risk HPVs from archived breast tumor tissue among Ethiopian women.
METHODS
METHODS
In this study, 75 breast cancer patients from Tikur Anbassa Specialized Hospital in Addis Ababa (Ethiopia) were included. HPV detection and genotyping were done using the novel Anyplex™ II HPV28 Detection Assay at the Orebro University Hospital, Sweden. The Anyplex™ II PCR System detects 19 high-risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 low-risk HPV types (6, 11, 40, 42, 43, 44, 54, 61, and 70). IHC for p16 was done using an automated system, the Dako Autostainer Link.
RESULTS
RESULTS
Out of the 75 valid tests, two were found to be positive (2.7%) for HPV. One of the cases was positive for the high-risk HPV16 genotype while the other was positive both for the high-risk HPV39 and the low-risk HPV6. The cell cycle protein p16 was highly expressed in the case positive for the high-risk HPV16, but it was not expressed in the case positive for HPV39.
CONCLUSION
CONCLUSIONS
The prevalence of HPV is low in Ethiopian breast cancer patients, but the role played by HPV in breast carcinogenesis among Ethiopian breast cancer patients cannot be commented based on these observations.
Identifiants
pubmed: 34671492
doi: 10.1155/2021/2140151
pmc: PMC8523267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2140151Informations de copyright
Copyright © 2021 Endale Gebregzabher et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Front Oncol. 2018 Jan 22;8:1
pubmed: 29404275
Lancet. 2007 Jul 7;370(9581):59-67
pubmed: 17617273
Infect Agent Cancer. 2019 Nov 11;14:36
pubmed: 31737087
PLoS One. 2020 May 6;15(5):e0232519
pubmed: 32374753
Breast Cancer Res Treat. 2012 Aug;135(1):1-15
pubmed: 22274134
PLoS One. 2015 Aug 21;10(8):e0136050
pubmed: 26295705
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Breast Cancer. 2018 Mar;25(2):127-133
pubmed: 29350329
Sci Rep. 2017 Feb 27;7:43591
pubmed: 28240743
Laryngoscope. 2016 Jun;126(6):1365-72
pubmed: 26707355
Infect Agent Cancer. 2014 Oct 08;9(1):33
pubmed: 25320636
Front Oncol. 2015 Dec 16;5:277
pubmed: 26734565
Front Oncol. 2016 Jan 08;5:298
pubmed: 26779441
Gland Surg. 2019 Oct;8(5):486-500
pubmed: 31741879
Front Oncol. 2016 Sep 29;6:207
pubmed: 27747193
J Med Virol. 2013 Feb;85(2):282-7
pubmed: 23160919
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Med Oncol. 2012 Mar;29(1):48-55
pubmed: 21318737
Cancer Lett. 2018 Apr 28;420:182-189
pubmed: 29410005
J Clin Virol. 2014 Oct;61(2):255-9
pubmed: 25088618
Int J Oncol. 2018 Mar;52(3):637-655
pubmed: 29393378